FACS dataset supporting paper "A preclinical randomized controlled multicenter trial of anti-IL-17A treatment for acute ischemic stroke"

This folder contains the raw fcs files and TTC stainings, used for  the study "A preclinical randomized controlled multicenter trial of anti-IL-17A treatment for acute ischemic stroke". 

See related materials in Collection at: https://doi.org/10.25452/figshare.plus.c.6371439 

Manuscript abstract
Multiple consensus statements have called for preclinical randomized controlled trials (pRCT) to improve translation in stroke research. We investigated the efficacy of an IL-17A neutralizing antibody in a multicenter pRCT using a murine ischemia reperfusion stroke model. Twelve week old, male C57BL/6 mice were subjected to 45 minutes of transient middle cerebral artery occlusion (tMCAO) in four centers. Mice were randomly assigned (1:1) to receive either an anti-IL-17A (500 µg) or isotype antibody (500 µg) intravenously one hour after reperfusion. The primary endpoint was infarct volume measured by MRI three days after tMCAO. Secondary analysis included mortality, neurological score, neutrophil infiltration and the impact of the gut microbiome on treatment effects. Out of 136 mice, 109 mice were included in the analysis of the primary endpoint. Mixed model analysis revealed that IL-17A neutralization significantly reduced infarct sizes (anti-IL-17A: 61.77 ± 31.04 mm3; IgG control: 75.66 ± 34.79 mm3; p=0.01). Secondary outcome measures showed a decrease in mortality (Hazard Ratio=3.43, 95% CI=1.157-10.18; p=0.04) and neutrophil invasion into ischemic cortices (anti-IL-17A: 7222 ± 6108 cells; IgG control: 28153 ± 23206 cells; p

本文件夹包含用于研究《A preclinical randomized controlled multicenter trial of anti-IL-17A treatment for acute ischemic stroke》（急性缺血性卒中抗IL-17A治疗的临床前随机对照多中心试验）的原始fcs文件和TTC染色样本。详见相关材料于：https://doi.org/10.25452/figshare.plus.c.6371439

稿件摘要
多项共识声明呼吁进行临床前随机对照试验（pRCT），以提升卒中研究中的转化研究。本研究调查了一种IL-17A中和抗体在多中心pRCT中的疗效，采用小鼠缺血再灌注卒中模型。12周龄的雄性C57BL/6小鼠在四个中心接受了45分钟的短暂大脑中动脉闭塞（tMCAO）。小鼠在再灌注后1小时内随机分配（1:1）接受抗IL-17A（500 µg）或同型抗体（500 µg）静脉注射。主要终点是在tMCAO后三天通过MRI测量的梗死体积。次要分析包括死亡率、神经功能评分、中性粒细胞浸润以及肠道菌群对治疗效果的影响。在136只小鼠中，109只小鼠被纳入主要终点的分析。混合模型分析显示，IL-17A中和显著减少了梗死体积（抗IL-17A组：61.77 ± 31.04 mm3；IgG对照组：75.66 ± 34.79 mm3；p=0.01）。次要结果指标显示死亡率降低（风险比=3.43，95%置信区间=1.157-10.18；p=0.04）和中性粒细胞侵入缺血皮质（抗IL-17A组：7222 ± 6108细胞；IgG对照组：28153 ± 23206细胞；p值待续）